Notification from the National Centre for Research and Development that the CT-01 project has been selected for funding for the second phase of this project

Current report No. 12/2024

Date of preparation: 23.05.2024

Subject: Notification from the National Centre for Research and Development that the CT-01 project has been selected for funding for the second phase of this project

Legal basis: Article 17(1) MAR - confidential information.

With reference to current reports 55/2023 of November 13, 2023 and 7/2024 of 6 March 2024, the Management Board of Captor Therapeutics S.A. based in Wrocław ("Company"), informs that the Company has received a letter from the National Centre for Research and Development recognizing the objection regarding the "phasing" of the CT-01 project (Discovery and development of a drug candidate for the treatment of hepatocellular carcinoma to eliminate cancer stem cells through induced degradation of an oncogenic transcription factor). The drug development program was selected for funding in the second phase of this Project and was placed on the ranking list of the FENG.01.01-IP.01-004/23 SMART Path - Phased Projects competition.

As part of the recognized objection, the Company will receive financing in the amount of up to
PLN 6 766 157,95.

The Company will inform for further proceedings as required by law.